羧酸酯酶1和2基因多态性在药物代谢中的研究进展

被引：7

作者：

刘帅兵 ^{[1
,2
]}

缪丽燕 ^{[1
,2
]}

机构：

[1] 苏州大学附属第一医院临床药理研究室

[2] 苏州大学药学院

来源：

中国临床药学杂志 | 2015年 / 24卷 / 03期

关键词：

羧酸酯酶1; 羧酸酯酶2; 药物代谢; 单核苷酸多态性;

D O I：

10.19577/j.cnki.issn10074406.2015.03.017

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

人类羧酸酯酶属于α/β水解酶家族,负责许多内源性和外源性化合物的水解,广泛位于药物代谢的主要组织,例如肝脏和小肠等。人羧酸酯酶主要有羧酸酯酶1(CES1)和2(CES2)。单核苷酸多态性(SNPs)对药物代谢酶的表达和(或)活性有重要的影响,这可能解释部分药物反应的个体差异。本篇综述主要介绍了由CES1和CES2单核苷酸多态性导致的CES酶多态性。对于含有酯键的药物,一些有意义的SNP可能影响CES酶的功能从而影响其药动学,进而对其药理和毒理作用发挥重要影响。

引用

页码：206 / 210

页数：5

共 18 条

[1]

羧酸酯酶基因1多态性鉴定及其与抗结核药物肝毒性相关性研究.[J].吴雪琼;朱冬林;张俊仙;钟逾;席云;安慧茹;梁艳;阳幼荣;.中华内科杂志.2012, 07

[2]

The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease [J].

Xie, Cheng ;

Ding, Xiaoliang ;

Gao, Jie ;

Wang, Haipeng ;

Hang, Yongfu ;

Zhang, Hua ;

Zhang, Jingjing ;

Jiang, Bin ;

Miao, Liyan .

PHARMACOGENETICS AND GENOMICS, 2014, 24 (04) :204-210

[3]

CES1A -816C as a Genetic Marker to Predict Greater Platelet Clopidogrel Response in Patients with Percutaneous Coronary Intervention [J].

Zou, Jian-Jun ;

Chen, Shao-Liang ;

Fan, Hong-Wei ;

Tan, Jie ;

He, Bang-Shun ;

Xie, Hong-Guang .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 63 (02) :178-183

[4]

Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding [J].

Pare, Guillaume ;

Eriksson, Niclas ;

Lehr, Thorsten ;

Connolly, Stuart ;

Eikelboom, John ;

Ezekowitz, Michael D. ;

Axelsson, Tomas ;

Haertter, Sebastian ;

Oldgren, Jonas ;

Reilly, Paul ;

Siegbahn, Agneta ;

Syvanen, Ann-Christine ;

Wadelius, Claes ;

Wadelius, Mia ;

Zimdahl-Gelling, Heike ;

Yusuf, Salim ;

Wallentin, Lars .

CIRCULATION, 2013, 127 (13) :1404-+

[5]

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response [J].

Lewis, Joshua P. ;

Horenstein, Richard B. ;

Ryan, Kathleen ;

O'Connell, Jeffrey R. ;

Gibson, Quince ;

Mitchell, Braxton D. ;

Tanner, Keith ;

Chai, Sumbul ;

Bliden, Kevin P. ;

Tantry, Udaya S. ;

Peer, Cody J. ;

Figg, William D. ;

Spencer, Shawn D. ;

Pacanowski, Michael A. ;

Gurbel, Paul A. ;

Shuldiner, Alan R. .

PHARMACOGENETICS AND GENOMICS, 2013, 23 (01) :1-8

[6]

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients [J].

Sai, Kimie ;

Saito, Yoshiro ;

Tatewaki, Naoko ;

Hosokawa, Masakiyo ;

Kaniwa, Nahoko ;

Nishimaki-Mogami, Tomoko ;

Naito, Mikihiko ;

Sawada, Jun-ichi ;

Shirao, Kuniaki ;

Hamaguchi, Tetsuya ;

Yamamoto, Noboru ;

Kunitoh, Hideo ;

Tamura, Tomohide ;

Yamada, Yasuhide ;

Ohe, Yuichiro ;

Yoshida, Teruhiko ;

Minami, Hironobu ;

Ohtsu, Atsushi ;

Matsumura, Yasuhiro ;

Saijo, Nagahiro ;

Okuda, Haruhiro .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) :222-233

[7]

Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.[J].Zsofia Nemoda;Nora Angyal;Zsanett Tarnok;Julia Gadoros;Maria Sasvari-Szekely.Neuropharmacology.2009, 7

[8]

Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients [J].

Fujiyama, N. ;

Miura, M. ;

Satoh, S. ;

Inoue, K. ;

Kagaya, H. ;

Saito, M. ;

Habuchi, T. ;

Suzuki, T. .

XENOBIOTICA, 2009, 39 (05) :407-414

[9]

Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes [J].

Fukami, Tatsuki ;

Nakajima, Miki ;

Maruichi, Taiga ;

Takahashi, Shiori ;

Takamiya, Masataka ;

Aoki, Yasuhiro ;

McLeod, Howard L. ;

Yokoi, Tsuyoshi .

PHARMACOGENETICS AND GENOMICS, 2008, 18 (10) :911-920

[10]

Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.[J].Hao-Jie Zhu;David I. Appel;Julie A. Johnson;Kenneth D. Chavin;John S. Markowitz.Biochemical Pharmacology.2008, 7

← 1 2 →